A Study of Gaboxadol in Primary Insomnia

Lundbeck

Status and phase: Completed; Phase 3

Conditions: Primary Insomnia

Treatments: Drug: Gaboxadol

Study type: Interventional

Funder types: Industry

Identifiers

NCT00209846

10402 (Other Identifier)

Details and patient eligibility

About

To evaluate the safety and tolerability of gaboxadol in primary insomnia.

Full description

To obtain long-term safety data in elderly patients with gaboxadol.

Sex: All

Ages: 66+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• patients with a diagnosis of primary insomnia

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind